With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Subscribe To Our Newsletter & Stay Updated
